Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple
myeloma, form immune synapses between T-cell surface marker CD3 and malignant cell …

Multiple myeloma is the second-most common hematologic malignancy in adults worldwide.
Despite ongoing advancement in therapeutic modalities, it remains an incurable disease …

Background Patients with relapsed/refractory multiple myeloma are at increased risk of
infection. Infections during treatment with teclistamab, the first B‐cell maturation antigen …

Bispecific antibodies [bsAb] targeting B-cell maturation antigen [BCMA] and G-protein-
coupled receptor class C group 5 member D [GPRC5D] have demonstrated deep and …

Introduction Multiple new drugs have been approved over the past 5 years for the treatment
of relapsed/refractory multiple myeloma (RRMM), and these are being increasingly widely …

Importance Cancer treatment can result in burdensome toxic effects that profoundly affect
patient quality of life. In seeking to emphasize the efficacy of tested treatments, clinical trial …

T-cell redirecting therapies, which include chimeric antigen receptor (CAR) T-cell therapy
and bispecific antibodies, have revolutionized the management of blood cancers. There are …

B-cell maturation antigen (BCMA)-directed T cell therapies such as idecabtagene vicleucel
(ide-cel), ciltacabtagene autoleucel (cilta-cel), teclistamab, and elranatamab have changed …

T cell–redirecting bispecific antibodies (BsAb) induce significant responses in heavily
pretreated multiple myeloma. BsAbs are currently administered in a dose-dense manner …

Immunotherapies have emerged as effective drugs for B-cell malignancies in the last
decade. Specifically, the use of therapies redirecting T cells against such tumors has shown …